CardioMEMS HF System

For pulmonary artery pressure monitoring

About the CardioMEMS HF System

The CardioMEMS™ HF System allows clinicians to monitor heart failure patients’ pulmonary artery (PA) pressure for proactive and actionable heart failure (HF) management and treatment. With early indications of worsening heart failure, you can remotely make adjustments to care to help slow the progression of heart failure, often before patients feel symptoms.

The CardioMEMS HF System is proven to:

Aid physicians in preventing worsening heart failure1, lowering mortality rates and improving survival^2,3,4
Significantly reduce heart failure hospitalizations^3,5
Improve quality of life in New York Heart Association (NYHA) Class III patients hospitalized for heart failure in the previous 12 months⁶

CardioMEMS HF System Product Information

CardioMEMS HF System Product Information

Indications

CardioMEMS HF System Indications and Usage: The CardioMEMS HF System is indicated for wirelessly measuring and monitoring pulmonary artery pressure and heart rate in NYHA Class II or III heart failure patients who either have been hospitalized for heart failure in the previous year and/or have elevated natriuretic peptides. The hemodynamic data are used by physicians for heart failure management with the goal of controlling pulmonary artery pressures and reducing heart failure hospitalizations.

Contraindications

The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.

How It Works

Review how the CardioMEMS HF System gathers PA pressure data and transmits to the Merlin.net™ Patient Care Network.

Order CardioMEMS HF System

Find model numbers, specification sheets and sales support information for components of the CardioMEMS HF System.

CardioMEMS HF System Clinical Evidence

Multiple clinical trials have evaluated the safety and effectiveness of the CardioMEMS HF System. For a deep dive into the clinical data, visit the Clinical Evidence and Journal Article information.

Key Clinical Outcomes

Reduction in Heart Failure Hospitalizations for HFpEF Patients⁷

Reduction in Heart Failure Hospitalizations for HFpEF Patients

Outstanding Safety Data

Outstanding Safety Data

Improved Survival^2,3,4

Improved Survival

CardioMEMS HF System Education and Training

For safe and reliable HF management with the CardioMEMS HF System, we provide comprehensive educational resources. The following are designed to help you and your patients better understand patient selection, implantation and care.

Patient Selection

Patient Education

Procedure Information

CardioMEMS HF System Coding Guide

This guide includes information regarding coverage, coding and reimbursement.
CardioMEMS HF System FAQ Guide

For the full resource list, visit Reimbursement & Coding for the CardioMEMS HF System.

Reimbursement & Coding

Manuals & Resources

Customer Service

Indications, Safety and Warnings

References

Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Current Heart Failure Reports. 2009;6:287-292.
Givertz MM, Stevenson LW, Costanzo MR, Bourge RC, Bauman JG, Ginn G, Abraham WT; CHAMPION Trial Investigators. Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2017
Abraham WT, Stevenson LW, Bourge RC, et al. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: Complete follow-up results from the CHAMPION randomised trial. Lancet. 2016;387(10017):453-461.
JoAnn Lindenfeld, on behalf of the GUIDE-HF, CHAMPION, and LAPTOPHF investigators. Longer Term Effects of Hemodynamic Monitoring on Outcomes: A Combined Data Analysis of patients with HFrEF in CHAMPION, GUIDE-HF, and LAPTOP-HF. Presented at THT Conference, Boston, MA, March 2023.
Desai AS, Bhimaraj A, Bharmi R, et al. Ambulatory hemodynamic monitoring reduces heart failure hospitalizations in “real-world” clinical practice. J Am Coll Cardiol. 2017;69(19):2357-65.
Abraham, W. T., Adamson, P. B., Bourge, R. C., Aaron, M., Costanzo, M. R., Stevenson, L. W., …Yadav, J. S., for the CHAMPION Trial Study Group. (2011). Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. The Lancet, 377(9766), 658-666. https://dx.doi.org/10.1016/S0140-6736(11)60101-3
Shavelle D. et al. Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure. Circulation: Heart Failure. Advance online publication. https://doi.org/10.1161/circheartfailure.119.006863

MAT-2006904 v4.0

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-1900882 v12.0